Accuray (ARAY) said Monday that it received approval from the Chinese National Medical Products Administration for its Radixact SynC and CyberKnife S7 System.
Radixact SynC is a radiation therapy system designed to deliver precise and personalized treatment to patients with cancer and CyberKnife S7 is a robotic radiosurgery device for treating cancerous and benign tumors, the company said.
Shares of the company were up 2.1% in recent trading.
Price: 2.19, Change: +0.04, Percent Change: +2.10
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。